VERU INC. (VERU) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
40/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinVERU / S&P 41.63% / 15.20% |
LoseVERU / S&P VERU unavailable / 15.00% |
LoseVERU / S&P VERU unavailable / 50.40% |
| 2026-Q11/3 |
WinVERU / S&P 3.27% / -4.33% |
LoseVERU / S&P VERU unavailable / 11.30% |
LoseVERU / S&P VERU unavailable / 27.70% |
| 2025-Q40/3 |
LoseVERU / S&P -43.68% / 2.65% |
LoseVERU / S&P VERU unavailable / 9.00% |
LoseVERU / S&P VERU unavailable / 13.40% |
| 2025-Q30/3 |
LoseVERU / S&P -34.48% / 8.12% |
LoseVERU / S&P VERU unavailable / 4.61% |
LoseVERU / S&P VERU unavailable / 13.45% |
| 2025-Q21/3 |
WinVERU / S&P 18.37% / 10.94% |
LoseVERU / S&P VERU unavailable / 4.83% |
LoseVERU / S&P VERU unavailable / 10.63% |
| 2025-Q10/3 |
LoseVERU / S&P -24.62% / -4.27% |
LoseVERU / S&P VERU unavailable / 4.98% |
LoseVERU / S&P VERU unavailable / 10.57% |
| 2024-Q40/3 |
LoseVERU / S&P -15.58% / 2.41% |
LoseVERU / S&P VERU unavailable / 5.25% |
LoseVERU / S&P VERU unavailable / 6.15% |
| 2024-Q30/3 |
LoseVERU / S&P -8.33% / 5.89% |
LoseVERU / S&P 3.62% / 5.89% |
LoseVERU / S&P VERU unavailable / 6.11% |
| 2024-Q21/3 |
WinVERU / S&P 20.00% / 4.28% |
LoseVERU / S&P -6.20% / 5.38% |
LoseVERU / S&P VERU unavailable / 5.12% |
| 2024-Q10/3 |
LoseVERU / S&P -2.78% / 10.56% |
LoseVERU / S&P -36.67% / 5.71% |
LoseVERU / S&P -79.41% / 5.59% |
| 2023-Q40/3 |
LoseVERU / S&P 0.00% / 11.69% |
LoseVERU / S&P -42.55% / 6.81% |
LoseVERU / S&P -52.05% / 7.78% |
| 2023-Q31/3 |
LoseVERU / S&P -39.50% / -3.27% |
LoseVERU / S&P -58.59% / 7.52% |
WinVERU / S&P 3.77% / -5.03% |
| 2023-Q21/3 |
LoseVERU / S&P 2.59% / 8.74% |
LoseVERU / S&P -71.34% / 9.50% |
WinVERU / S&P 128.81% / -8.57% |
| 2023-Q11/3 |
LoseVERU / S&P -78.03% / 7.50% |
LoseVERU / S&P -64.80% / 10.77% |
WinVERU / S&P 400.00% / -15.69% |
| 2022-Q41/3 |
LoseVERU / S&P -54.17% / 7.56% |
LoseVERU / S&P -54.38% / 11.88% |
WinVERU / S&P 630.00% / -17.99% |
| 2022-Q31/3 |
WinVERU / S&P 1.95% / -4.88% |
LoseVERU / S&P -35.76% / 13.47% |
LoseVERU / S&P -1063.64% / -1.41% |
| 2022-Q22/3 |
WinVERU / S&P 133.95% / -16.10% |
LoseVERU / S&P -8.63% / 13.71% |
WinVERU / S&P 5800.00% / 11.04% |
| 2022-Q12/3 |
LoseVERU / S&P -18.00% / -4.60% |
WinVERU / S&P 20.86% / 15.97% |
WinVERU / S&P 1033.33% / 42.23% |
| 2021-Q42/3 |
LoseVERU / S&P -30.95% / 11.03% |
WinVERU / S&P 30.34% / 15.00% |
WinVERU / S&P 720575940379279360.00% / 96.40% |
| 2021-Q32/3 |
WinVERU / S&P 5.70% / 0.58% |
WinVERU / S&P 43.83% / 10.77% |
LoseVERU / S&P -139.29% / 69.42% |
| 2021-Q21/3 |
LoseVERU / S&P -25.14% / 8.55% |
WinVERU / S&P 44.96% / 6.58% |
LoseVERU / S&P VERU unavailable / 51.81% |
| 2021-Q12/3 |
WinVERU / S&P 24.62% / 6.17% |
WinVERU / S&P 28.36% / -1.06% |
LoseVERU / S&P VERU unavailable / 7.39% |
| 2020-Q42/3 |
WinVERU / S&P 230.15% / 12.15% |
WinVERU / S&P 29.50% / -3.72% |
LoseVERU / S&P VERU unavailable / -33.42% |
| 2020-Q31/3 |
LoseVERU / S&P -21.56% / 8.93% |
WinVERU / S&P 33.92% / -2.04% |
LoseVERU / S&P VERU unavailable / -27.10% |
| 2020-Q21/3 |
LoseVERU / S&P 2.14% / 20.54% |
WinVERU / S&P 39.94% / -0.46% |
LoseVERU / S&P VERU unavailable / -27.11% |
| 2020-Q12/3 |
WinVERU / S&P -2.39% / -19.60% |
WinVERU / S&P 62.05% / 3.47% |
LoseVERU / S&P VERU unavailable / -14.75% |
| 2019-Q42/3 |
WinVERU / S&P 55.09% / 9.07% |
WinVERU / S&P 83.26% / 5.36% |
LoseVERU / S&P VERU unavailable / 2.99% |
| 2019-Q31/3 |
LoseVERU / S&P 1.41% / 1.70% |
WinVERU / S&P 100.47% / 5.02% |
LoseVERU / S&P VERU unavailable / 0.21% |
| 2019-Q22/3 |
WinVERU / S&P 45.89% / 4.30% |
WinVERU / S&P 97.01% / 6.64% |
LoseVERU / S&P VERU unavailable / 8.65% |
| 2019-Q11/3 |
LoseVERU / S&P 4.29% / 13.65% |
WinVERU / S&P 82.69% / 8.12% |
LoseVERU / S&P VERU unavailable / 14.29% |
| 2018-Q42/3 |
WinVERU / S&P -1.41% / -13.52% |
WinVERU / S&P 51.17% / 9.05% |
LoseVERU / S&P VERU unavailable / 18.23% |
| 2018-Q31/3 |
LoseVERU / S&P -29.70% / 7.71% |
WinVERU / S&P 16.18% / 10.21% |
LoseVERU / S&P VERU unavailable / 19.06% |
| 2018-Q21/3 |
WinVERU / S&P 11.60% / 3.43% |
LoseVERU / S&P 6.12% / 9.03% |
LoseVERU / S&P VERU unavailable / 14.46% |
| 2018-Q11/3 |
WinVERU / S&P 58.77% / -0.76% |
LoseVERU / S&P -10.88% / 7.68% |
LoseVERU / S&P VERU unavailable / 12.46% |
| 2017-Q40/3 |
LoseVERU / S&P -56.98% / 6.64% |
LoseVERU / S&P -24.16% / 7.03% |
LoseVERU / S&P VERU unavailable / 13.82% |
| 2017-Q31/3 |
WinVERU / S&P 152.38% / 4.48% |
LoseVERU / S&P -38.29% / 5.68% |
LoseVERU / S&P -2600.00% / 17.57% |
| 2017-Q21/3 |
WinVERU / S&P 3.96% / 3.09% |
LoseVERU / S&P -47.41% / 4.83% |
LoseVERU / S&P -311.11% / 17.74% |
| 2017-Q11/3 |
WinVERU / S&P 10.99% / 6.07% |
LoseVERU / S&P -47.19% / 3.67% |
LoseVERU / S&P -227.27% / 13.32% |
| 2016-Q40/3 |
LoseVERU / S&P -25.41% / 3.82% |
LoseVERU / S&P -49.85% / 2.09% |
LoseVERU / S&P -147.06% / 7.05% |
| 2016-Q30/3 |
LoseVERU / S&P -3.17% / 3.85% |
LoseVERU / S&P -32.13% / 0.20% |
LoseVERU / S&P -93.33% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VERU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -15.69% | 20.78% |
| Annualized return | -15.69% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VERU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.92% | 83.14% |
| Annualized return | -50.14% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VERU total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -78.92% | 319.30% |
| Annualized return | -14.42% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |